Six months of the GLP-1 RAs dulaglutide treatment (0.75 mg/weekly) compared with the DPP-4i teneligliptin (20 mg/daily) significantly reduced SMI (−1.2%) in patients with T2DM treated with insulin and on hemodialysis. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.